Search Result

Results for "

HLA-A2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (2) Biochemical Assay Reagents (1) EBV (2) EGFR (1) HCV (1) HPV (3) IFNAR (1) LILRB (1) MHC (2) Small Interfering RNA (siRNA) (2) TNF Receptor (1) Tyrosinase (1)
By Research Areas:	Cancer (12) Infection (2) Inflammation/Immunology (5)
Oligonucleotides:	Human Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy ^[2].

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) ^[2].

HY-P1778A

HPV16 E7 (86-93) TFA	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas ^[2].

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy ^[2].

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy ^[2].

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P991247

*Anti-HLA-A2* (Hu8F4)**	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA-A2* (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2* in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas ^[2].

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HY-P991787

*Anti-HLA-A2* Antibody (BB7.2)**	MHC	Inflammation/Immunology
Anti-HLA-A2 Antibody (BB7.2) reacts with the alpha subunit of the human leukocyte antigen-A2 (HLA-A2). Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HY-RS06208

HLA-DQB2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB2 Human Pre-designed siRNA Set A HLA-DQB2 Human Pre-designed siRNA Set A

HY-RS06206

HLA-DQA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQA2 Human Pre-designed siRNA Set A HLA-DQA2 Human Pre-designed siRNA Set A

HY-P5294

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-106187B

MART-1 (27-35) (human) TFA		Cancer
MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma ^[2].

HY-P992353

ES009	LILRB	Cancer
ES009 is a high-affinity *LILRB2* antagonist, with IC₅₀ values of 14.07 nM and 18.61 nM for inhibiting *hLILRB2-huANGPTL3* and *hLILRB2-huANGPTL4*, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer ^[2] .

Cat. No.	Product Name	Target	Research Area